Nextrials' Prism Supports Apple iPad for Mobile Access to Patient Data in the Clinical Trial and Healthcare Setting

Article

Company News Release

Nextrials, Inc. announced that the latest version of its Prism™ electronic data capture (EDC) and clinical trial data management platform will now support anytime/anywhere data access via the Apple® iPad™ slate computer.  Because Prism 3.0 is fully integrated with platforms traditionally used for electronic health records (EHR) within the healthcare setting, its compatibility with the iPad enables physicians, researchers, and others to have real-time access to data regardless of locale, and delivers that data in the familiar graphical formats traditionally generated by Prism on a desktop computer.

“With its bigger screen, imaging power and a number of medical applications in development, the Apple iPad is expected to quickly advance the idea of entering data at the bedside for use in both clinical trials and a patient’s permanent electronic health record,” noted James Rogers, CEO and co-founder of Nextrials.  “As usage of an integrated EDC/EHR platform continues to grow, Prism’s compatibility with the iPad and the Apple® iPhone™ becomes increasingly important for multi-site organizations and ones where immediate access to ongoing data is critical.”

The iPad has the potential of meeting many specific healthcare needs, such as serving as a handheld terminal for physician-led grand rounds, the examination of x-rays at remote locations and histology reviews.  In the clinical trial setting, it can give researchers instant access to adverse event data, patient recruitment status, supply availability and other critical real-time data.

Nextrials’ Prism combines clinical trial management functionality with EDC. By receiving a constant flow of data, Prism allows sponsors and sites to utilize real-time integration of disparate information and data sources, such as a hospital’s EHR or patient records.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.